2024-11-29 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**1. Performance Comparison with S&P 500 (VOO):**

Eli Lilly and Co. (LLY) is a leading pharmaceutical company.  The cumulative return of LLY is 624.48%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 128.86%.  The difference is 495.6%, placing it at the 73.7th percentile of its historical performance relative to the S&P 500.  The provided CAGR data further emphasizes LLY's strong outperformance over various periods.

**2. Recent Price Movement:**

* **Closing Price:** $788.19 (Last Market: $788.61)
* **5-Day Moving Average:** $766.09
* **20-Day Moving Average:** $784.39
* **60-Day Moving Average:** $865.17

The price is slightly below its 20-day moving average and significantly below its 60-day moving average, suggesting a recent downward trend.

**3. Technical Indicators and Expected Return:**

* **RSI:** 48.13 (Slightly below neutral; not indicating overbought or oversold conditions)
* **PPO:** 0.47 (Positive, suggesting potential upward momentum)
* **Relative Strength Change (20-day):** -9.0% (Short-term downward pressure)
* **Expected Return (2+ years):** 578.1% (Significant outperformance relative to the S&P 500 expected over the long term).  Given the current price of $788.61, and the significant outperformance, there is no indication of a rapid price jump or drop.  The high expected return suggests continued positive market outlook.

**4. Recent Earnings Analysis:**

The provided earnings data shows significant volatility in EPS, with a large increase from Q2 2024 to Q3 2024 ($3.29 to $1.08). Revenue has generally been stable, ranging from $8.77B to $11.44B over the reported period.  There's a notable negative EPS in November 2023 and October 2024, which warrants further investigation beyond the presented data to understand the underlying reasons.  The analysis is limited by the lack of context (e.g., analyst expectations).

**5. Financial Information Analysis:**

* **Revenue:** Revenue shows relatively consistent performance, with some fluctuations between quarters.
* **Profit Margin:** Profit margins are consistently high (around 80%), indicating strong profitability.
* **Equity & ROE:** Equity shows growth, however ROE fluctuates significantly, potentially indicating variability in investment returns and efficiency.  A negative ROE in Q3 2023 warrants further investigation to understand contributing factors.

**6. News and Recent Issues:**

This section requires additional information. The provided data does not include news, market outlook, or analyst opinions.

**7. Overall Analysis:**

LLY shows significant outperformance compared to the S&P 500, with high cumulative returns and a strong expected return over the long term.  However, recent price action suggests a short-term downward trend.  While profitability is consistently strong,  EPS exhibits notable volatility, and ROE's significant fluctuation demands further investigation into the underlying drivers.  Additional news and analyst information would provide a more complete picture.  The high expected return is encouraging for long-term investors, but the short-term price fluctuations and some concerning data points in the recent earnings and ROE necessitate a cautious approach.  Further investigation into the reasons behind the negative EPS and fluctuating ROE is crucial before making any investment decisions.

**8. Disclaimer:** This analysis is based solely on the provided data.  It is not financial advice and should not be the sole basis for investment decisions. Independent research and consultation with a financial advisor are recommended before making any investment choices.  Missing context (such as analyst expectations, news events, specific reasons for the fluctuating ROE and negative EPS) prevents a comprehensive and thorough analysis.
